Statements (42)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Person
|
gptkbp:advocates_for |
personalized medicine
|
gptkbp:affiliation |
gptkb:Ionis_Pharmaceuticals
|
gptkbp:alma_mater |
gptkb:University_of_California,_San_Francisco
|
gptkbp:awards |
multiple patents in drug development
|
gptkbp:birth_place |
gptkb:United_States
|
gptkbp:children |
not publicly disclosed
|
gptkbp:collaborated_with |
various academic institutions
|
gptkbp:contribution |
advancing genetic therapies
development of antisense oligonucleotide drugs |
gptkbp:education |
gptkb:University_of_California,_San_Diego
|
gptkbp:field |
pharmaceutical research
|
gptkbp:founded |
Ionis Pharmaceuticals in 1989
|
gptkbp:goal |
improving patient outcomes
|
https://www.w3.org/2000/01/rdf-schema#label |
Stanley T. Crooke
|
gptkbp:impact |
advancements in RNA therapeutics
|
gptkbp:influence |
drug discovery processes
|
gptkbp:influenced |
pharmaceutical industry practices
|
gptkbp:influenced_by |
gptkb:Robert_W._Holley
|
gptkbp:inspiration |
in the field of biomedicine
|
gptkbp:invention |
over 100 patents
first FDA-approved antisense drug |
gptkbp:involvement |
biotechnology sector
|
gptkbp:known_for |
antisense technology
founding Ionis Pharmaceuticals |
gptkbp:leadership |
gptkb:Ionis_Pharmaceuticals
innovative and collaborative |
gptkbp:legacy |
pioneering work in antisense technology
|
gptkbp:nationality |
gptkb:American
|
gptkbp:occupation |
gptkb:Scientist
|
gptkbp:philosophy |
patient-centered drug development
|
gptkbp:position |
CEO of Ionis Pharmaceuticals
|
gptkbp:publications |
numerous scientific articles
|
gptkbp:recognition |
leader in RNA therapeutics
|
gptkbp:research_areas |
genetic medicine
|
gptkbp:research_focus |
RNA-targeted therapeutics
|
gptkbp:spouse |
not publicly disclosed
|
gptkbp:vision |
transforming medicine through RNA technology
|
gptkbp:years_active |
1980s-present
|
gptkbp:bfsParent |
gptkb:Ionis_Pharmaceuticals
gptkb:SGMO |
gptkbp:bfsLayer |
5
|